ANI Pharmaceuticals, Inc. (ANIP)

Market Cap	1.74B +19.4%
Revenue (ttm)	883.37M +43.8%
Net Income	70.22M
EPS	3.32
Shares Out	22.75M
PE Ratio	23.01
Forward PE	8.45
Dividend	n/a
Ex-Dividend Date	n/a

Volume	229,771
Open	78.29
Previous Close	78.29
Day's Range	75.88 - 78.46
52-Week Range	56.71 - 99.50
Beta	0.44
Analysts	Strong Buy
Price Target	110.00 (+43.83%)
Earnings Date	May 8, 2026

About ANIP

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, gr...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 970
• Stock Exchange: NASDAQ
• Ticker Symbol: ANIP
• Website: https://www.anipharmaceuticals.com

Analyst Summary

According to 5 analysts, the average rating for ANIP stock is "Strong Buy." The 12-month stock price target is $110.0, which is an increase of 43.83% from the latest price.

Price Target

$110.0

(43.83% upside)

Analyst Consensus: Strong Buy